pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,005 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT811Endpoints608BioPharma Dive232onclive165Fierce Biotech78BioSpace78raps32fda press20globenewswire health
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • BioNTech to scale down manufacturing, over 1,800 jobs on the line
    BioNTech is making big cuts to its manufacturing footprint. The German company said in its first-quarter earnings release that up to 1,860 manufacturing staff could be impacted by its planned downs…
    Endpoints · 2mo ago↗ source
  • Parsley Health goes in-network nationwide
    When I first heard about Parsley Health close to a decade ago, the startup embodied a few trends I was following closely: primary care startups and cash-pay healthcare. For a ...
    Endpoints · 2mo ago↗ source
  • Breast Cancer Experts Preview Abstracts to Watch at the 2026 ESMO Breast Cancer Congress
    Experts in a range of breast cancer subtypes highlight research data being presented at the 2026 ESMO Breast Cancer Congress.
    onclive · 2mo ago
← prev
page 35 of 41
next →
20
fda recalls20
fda medwatch16
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
↗ source
  • Viridian data lift prospects for thyroid eye disease drug
    Whereas earlier Phase 3 results disappointed Wall Street, new findings in people with “chronic” disease were viewed by analysts as much more competitive with Amgen’s Tepezza.
    BioPharma Dive · 2mo ago↗ source
  • The Type of Fat—Not the Amount—Fuels Pancreatic Cancer
    Research from Yale Cancer Center showed that the type of fat consumed may matter more than amount in pancreatic cancer.
    onclive · 2mo ago↗ source
  • Second life for gene therapy; Takeda Phase 2/3 win; UK cancer biotech's $83M
    A blood test might predict who will respond to Wegovy; Viridian's thyroid eye disease drug wins another Phase 3; Ideaya drops two GSK-returned assets. 🧬 Second life for a gene therapy: A Cleveland…
    Endpoints · 2mo ago↗ source
  • Swiss manufacturing, biotech industry so far unfazed by geopolitics
    BASEL, Switzerland — Pharma manufacturing in Switzerland appears to be unperturbed by the threat of tariffs, but it might take several years before the impact of companies moving production to the…
    Endpoints · 2mo ago↗ source
  • Pfizer ends Trillium-related development as R&D spend jumps
    Pfizer has discontinued the final clinical study stemming from its 2021 acquisition of Trillium Therapeutics, funneling cash primarily toward a host of other cancer and obesity studies. The company…
    Endpoints · 2mo ago↗ source
  • Microbiome startup raises $48M for immunotherapy and malnutrition treatments
    Scientists trying to understand why cancer immunotherapy works so well for some patients and not others have found a potential answer in one cancer survivor's poop. A biotech startup has studied th…
    Endpoints · 2mo ago↗ source
  • J&J's IBD combo fails Phase 2 studies, but will move into pivotal testing
    Johnson & Johnson will move a treatment for inflammatory bowel disease into Phase 3 studies despite the therapy's failure in two mid-stage trials. The company said that JNJ-4804, a combination of t…
    Endpoints · 2mo ago↗ source
  • Iopofosine I 131 Follow-Up Data Show Strong Efficacy in Waldenström Macroglobulinemia
    Iopofosine I 131 produced strong responses in Waldenström macroglobulinemia, according to 12-month folllow-up data from CLOVER WaM requested by the FDA.
    onclive · 2mo ago↗ source
  • Dr McGregor on Key End Points of the STRIKE Trial of Tivozanib Plus Pembrolizumab in RCC
    Bradley McGregor, MD, discusses the end points that will be evaluated in the phase 3 STRIKE trial of adjuvant tivozanib plus pembrolizumab in high-risk RCC.
    onclive · 2mo ago↗ source
  • Madrigal extends MASH deal streak with Arrowhead drug that J&J didn't want
    Madrigal Pharmaceuticals has made its fourth MASH deal in 10 months, further signaling its ambitions to be not just the first drugmaker for the fatty liver disease, but also the owner of the field'…
    Endpoints · 2mo ago↗ source
  • Healthcare organizations are increasingly building their own AI tools
    Big healthcare organizations are increasingly building their own AI tools, rather than shelling out for tools made by health tech startups that may eventually become free. It’s not uncommon to find…
    Endpoints · 2mo ago↗ source
  • Dr Kuykendall on the Evolving JAK Inhibitor and Transplant Considerations in Myelofibrosis
    Andrew Kuykendall, MD, explains considerations for JAK inhibitor sequencing and the use of transplant in myelofibrosis.
    onclive · 2mo ago↗ source
  • Vertex earnings get muted investor response
    While overall revenue fell just shy of Wall Street forecasts, sales of the gene editing medicine Casgevy and pain drug Journavx missed analyst estimates by double-digit percentages.
    BioPharma Dive · 2mo ago↗ source
  • Cytokinetics heart drug scores in closely watched trial
    Myqorzo’s success in “non-obstructive” hypertrophic cardiomyopathy separates it from Bristol Myers Squibb’s rival Camzyos and opens up a multibillion-dollar market opportunity.
    BioPharma Dive · 2mo ago↗ source
  • New Endometrial Targets Beyond HER2
    Interest in endometrial cancer extends well beyond HER2, and the faculty review a growing pipeline of antibody drug conjugates directed at additional targets. Discussion includes why TROPE2 and oth…
    onclive · 2mo ago↗ source
  • Coordinating Care in Multiple Myeloma Across Practice Settings
    onclive · 2mo ago↗ source
  • EGFR-Mutated NSCLC: Molecular Reassessment at Disease Progression
    In this case-based segment, Dr. Sands presents a patient with EGFR-mutated metastatic non-small cell lung cancer who has progressed after first-line combination therapy with an EGFR tyrosine kinase…
    onclive · 2mo ago↗ source
  • New Understandings of Treatments, End Points, and Disease Biology Expand MCL Horizons
    Lore Gruenbaum, PhD, discusses the direction mantle cell lymphoma is headed in addition to other critical areas of unmet needs.
    onclive · 2mo ago↗ source
  • Cytokinetics succeeds where Bristol Myers failed in heart muscle disease
    Cytokinetics’ pill for a heart muscle disorder called hypertrophic cardiomyopathy could see its addressable market double after it succeeded in a pivotal trial for another form of the disease. The…
    Endpoints · 2mo ago↗ source
  • Cytospire hauls in $83M for a new type of T cell engager
    The British biotechnology startup is making "pan-gamma delta” T cell engagers it says can address the limitations of similar, existing therapies.
    BioPharma Dive · 2mo ago↗ source
  • Vertex drops mRNA cystic fibrosis program over 'tolerability' issues
    Vertex Pharmaceuticals said it has dropped development of an mRNA-based cystic fibrosis therapy after facing challenges similar to those that have troubled other parts of the field in delivering th…
    Endpoints · 2mo ago↗ source
  • FDA search for new CBER head focused on small group of final candidates
    The FDA has narrowed its search for a new leader of its Center for Biologics Evaluation and Research to three or four final candidates, according to a person familiar with the matter. The agency ho…
    Endpoints · 2mo ago↗ source